Next 10 |
home / stock / mpsyy / mpsyy news
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 24, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer (CEO). The appointment will take effec...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 22, 2019 / MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019. MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today p...
Conference call and webcast (in English) to be held on May 8, 2019 at 2:00pm CEST (1:00pm BST/8:00am EDT) - MOR208: Rolling submission of L-MIND study data to FDA to support potential approval in the U.S. on track - David Trexler hired as President, MorphoSys US Inc.; build-up of c...
PLANEGG/MUNICH, GERMANY and SHANGHAI, CHINA / ACCESSWIRE / April 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 10, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that it has published its agenda for the Company's ordinary Annual General Meeting (AGM), which will take place on Wednesday, May 22, 2019. ...
MUNICH, GERMANY / ACCESSWIRE / April 9, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conferences: Kempen Life Sciences Conference Date: April 16, 2019 Venue: Amsterdam, Netherlands Presenter: Dr. Sarah Fakih, Head of ...
PLANEGG/MUNICH GERMANY / ACCESSWIRE / April 1, 2019 / Dr. Sarah Fakih joined MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) as Vice President and Head of Corporate Communications and Investor Relations effective April 1, 2019. She will report to Chief Financia...
Conference call and webcast (in English) tomorrow, March 14, 2019 at 2:00pm CET (1:00pm GMT/9:00am EDT) Highlights in R&D and corporate development - Interim data from all patients enrolled in ongoing L-MIND trial of MOR208 in combination with lenalidomide in relapsed/refr...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / March 4, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; Nasdaq: MOR) will publish its Annual Financial Results 2018 on March 13, 2019 at 10:00pm CET (9:00pm GMT; 5:00pm EDT). The Management team of MorphoSys AG will host a ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 21, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conference: 8th Annual Leerink Partners Global Healthcare Conference Date: February 28, 2019, 2:30 pm EST (8:30 pm ...
News, Short Squeeze, Breakout and More Instantly...
Morphosys Ag Sp/Adr Company Name:
MPSYY Stock Symbol:
OTCMKTS Market:
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 24, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer (CEO). The appointment will take effec...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 22, 2019 / MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019. MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today p...
Conference call and webcast (in English) to be held on May 8, 2019 at 2:00pm CEST (1:00pm BST/8:00am EDT) - MOR208: Rolling submission of L-MIND study data to FDA to support potential approval in the U.S. on track - David Trexler hired as President, MorphoSys US Inc.; build-up of c...